Literature DB >> 7880122

Rheumatoid arthritis, corticosteroid therapy and hip fracture.

C Cooper1, C Coupland, M Mitchell.   

Abstract

OBJECTIVE: To identify the risk of hip fracture in patients with rheumatoid arthritis and those taking corticosteroids.
METHODS: In a population based case-control study, we compared 300 consecutive patients with hip fracture aged 50 years and over from a defined district and 600 age and sex matched community controls.
RESULTS: The risk of hip fracture was increased in patients with rheumatoid arthritis (odds ratio (OR) 2.1; 95% confidence interval (CI) 1.0 to 4.7) and those receiving corticosteroids (OR 2.7; 95% CI 1.2 to 5.8). The risk attributable to rheumatoid arthritis was markedly reduced by adjusting for functional impairment, while that for steroid use remained after adjusting for body mass index, smoking, alcohol, and functional status.
CONCLUSIONS: Hip fracture risk is approximately doubled amongst patients with rheumatoid arthritis and among those taking steroids. These risk increases are, to some extent, independent of each other. In rheumatoid arthritis, the risk was most closely associated with functional impairment, whereas steroid use did not appear to be confounded by this variable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7880122      PMCID: PMC1005512          DOI: 10.1136/ard.54.1.49

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

2.  Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy.

Authors:  R C Butler; M W Davie; M Worsfold; C A Sharp
Journal:  Br J Rheumatol       Date:  1991-04

3.  Osteoporosis of rheumatoid arthritis: influence of age, sex and corticosteroids.

Authors:  P D Saville; O Kharmosh
Journal:  Arthritis Rheum       Date:  1967-10

4.  Fractures in rheumatoid arthritis: an evaluation of associated risk factors.

Authors:  B A Michel; D A Bloch; F Wolfe; J F Fries
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

5.  Relationship between local and total bone mineral in patients with rheumatoid arthritis and normal subjects.

Authors:  O Skibsted Als; A Gotfredsen; C Christiansen
Journal:  Clin Rheumatol       Date:  1983-09       Impact factor: 2.980

6.  Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids.

Authors:  M J Garton; D M Reid
Journal:  Arthritis Rheum       Date:  1993-02

7.  Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

Authors:  M Luengo; C Picado; L Del Rio; N Guañabens; J M Montserrat; J Setoain
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

8.  Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment.

Authors:  D M Reid; N S Kennedy; M A Smith; P Tothill; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

9.  Alterations in appendicular skeletal mass in patients with rheumatoid, psoriatic, and osteoarthropathy.

Authors:  C Cooper; V Poll; M McLaren; S O Daunt; M I Cawley
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

10.  Risk of vertebral fracture in women with rheumatoid arthritis.

Authors:  T D Spector; G M Hall; E V McCloskey; J A Kanis
Journal:  BMJ       Date:  1993-02-27
View more
  82 in total

1.  Management of bone disease in patients on long term glucocorticoid therapy.

Authors:  J E Compston
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  Glucocorticoids in the treatment of early and late RA.

Authors:  J W J Bijlsma; M Boers; K G Saag; D E Furst
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  [Insufficiency fractures of the feet and lower limbs in rheumatoid arthritis].

Authors:  J Pauser; H-D Carl; B Swoboda; K A Jendrissek
Journal:  Z Rheumatol       Date:  2011-12       Impact factor: 1.372

Review 4.  Assessment of fracture risk.

Authors:  Sanford Baim; William D Leslie
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

5.  [Insufficiency fractures in rheumatology. Case report and overview].

Authors:  R Dreher; F Buttgereit; W Demary; B Görtz; G Hein; P Kern; A Schulz
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

6.  Bone microarchitecture in males with corticosteroid-induced osteoporosis.

Authors:  D Chappard; N Josselin; C Rougé-Maillart; E Legrand; M F Baslé; M Audran
Journal:  Osteoporos Int       Date:  2006-11-22       Impact factor: 4.507

7.  Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.

Authors:  L Dalle Carbonare; F Bertoldo; M T Valenti; S Zordan; S Sella; A Fassina; G Turco; G Realdi; V Lo Cascio; S Giannini
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Risk of acetabular protrusion is low in rheumatoid arthritis patients treated with bipolar hemiarthroplasty for displaced femoral neck fractures without rheumatoid change in hip joints.

Authors:  Yu Mori; Naoko Mori; Taketo Mori; Satoshi Nakamura; Masato Ishizuka; Tokuhisa Sano; Eiji Itoi
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-11-27

9.  Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients.

Authors:  Philip M Grant; Virginia Sheikh; Rebecca DerSimonian; Adam Rupert; Gregg Roby; Alice Pau; Michael C Sneller; Sheryl-Vi Rico; Todd T Brown; Irini Sereti
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-21       Impact factor: 2.205

Review 10.  Prevention and treatment of postmenopausal osteoporosis.

Authors:  R B Hallworth
Journal:  Pharm World Sci       Date:  1998-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.